Westpac Banking Corp raised its position in shares of Baxter International Inc (NYSE:BAX) by 5.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 256,418 shares of the medical instruments supplier’s stock after purchasing an additional 12,276 shares during the quarter. Westpac Banking Corp owned 0.05% of Baxter International worth $21,001,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the company. SeaCrest Wealth Management LLC raised its position in shares of Baxter International by 2.0% during the second quarter. SeaCrest Wealth Management LLC now owns 6,117 shares of the medical instruments supplier’s stock valued at $501,000 after buying an additional 122 shares during the last quarter. Boston Private Wealth LLC increased its position in Baxter International by 1.8% in the second quarter. Boston Private Wealth LLC now owns 7,346 shares of the medical instruments supplier’s stock worth $602,000 after purchasing an additional 129 shares during the last quarter. Brookstone Capital Management increased its position in Baxter International by 4.0% in the second quarter. Brookstone Capital Management now owns 3,422 shares of the medical instruments supplier’s stock worth $280,000 after purchasing an additional 131 shares during the last quarter. Horrell Capital Management Inc. increased its position in Baxter International by 0.4% in the first quarter. Horrell Capital Management Inc. now owns 31,167 shares of the medical instruments supplier’s stock worth $2,534,000 after purchasing an additional 138 shares during the last quarter. Finally, Cornerstone Advisors Inc. increased its position in Baxter International by 5.1% in the second quarter. Cornerstone Advisors Inc. now owns 2,856 shares of the medical instruments supplier’s stock worth $234,000 after purchasing an additional 139 shares during the last quarter. Hedge funds and other institutional investors own 83.96% of the company’s stock.

Several equities research analysts recently weighed in on the stock. Raymond James boosted their price target on shares of Baxter International from $84.00 to $95.00 and gave the stock an “outperform” rating in a research report on Friday, July 26th. Zacks Investment Research upgraded shares of Baxter International from a “hold” rating to a “buy” rating and set a $86.00 price target on the stock in a research report on Friday, June 21st. Piper Jaffray Companies boosted their price target on shares of Baxter International from $90.00 to $95.00 and gave the stock an “overweight” rating in a research report on Thursday, July 25th. Royal Bank of Canada set a $87.00 price target on shares of Baxter International and gave the stock a “hold” rating in a research report on Friday, July 26th. Finally, Cowen set a $75.00 price target on shares of Baxter International and gave the stock a “hold” rating in a research report on Monday, April 22nd. Four equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $85.27.

In other news, SVP Jacqueline Kunzler sold 593 shares of the business’s stock in a transaction on Wednesday, June 19th. The shares were sold at an average price of $80.46, for a total transaction of $47,712.78. Following the completion of the sale, the senior vice president now directly owns 9,023 shares of the company’s stock, valued at $725,990.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Third Point Llc sold 5,000,000 shares of the business’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $76.37, for a total transaction of $381,850,000.00. The disclosure for this sale can be found here. Insiders have sold 5,001,913 shares of company stock worth $382,000,950 in the last quarter. Company insiders own 0.70% of the company’s stock.

BAX stock traded up $2.43 during mid-day trading on Tuesday, reaching $88.03. 2,605,742 shares of the stock traded hands, compared to its average volume of 2,358,087. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.78 and a quick ratio of 2.10. Baxter International Inc has a one year low of $61.05 and a one year high of $86.68. The firm has a market cap of $44.09 billion, a PE ratio of 28.86, a PEG ratio of 1.99 and a beta of 1.00. The company has a 50-day simple moving average of $83.21.

Baxter International (NYSE:BAX) last posted its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $0.89 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.81 by $0.08. Baxter International had a net margin of 14.28% and a return on equity of 21.21%. The business had revenue of $2.84 billion for the quarter, compared to analysts’ expectations of $2.80 billion. During the same quarter in the previous year, the business posted $0.77 earnings per share. The business’s revenue was down .1% compared to the same quarter last year. As a group, equities analysts anticipate that Baxter International Inc will post 3.37 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 1st. Shareholders of record on Friday, August 30th will be given a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 1.00%. The ex-dividend date of this dividend is Thursday, August 29th. Baxter International’s dividend payout ratio (DPR) is 28.85%.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Further Reading: What is the price-to-earnings growth (PEG) ratio?

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.